High Risk Neuroblastoma

DrugDrug NameDrug Description
DB00041AldesleukinA recombinant analog of interleukin-2 used to induce an adaptive immune response in the treatment of renal cell carcinoma.
DB09077DinutuximabAn immunotherapeutic agent used in combination with other immunomodulating agents to treat high-risk neuroblastoma in pediatric patients who achieve at least a partial response to prior first-line multiagent, multimodality therapy.
DrugDrug NamePhaseStatusCount
DB00958Carboplatin2Active Not Recruiting1
DB00531Cyclophosphamide2Active Not Recruiting1
DB00773Etoposide2Active Not Recruiting1
DB01042Melphalan2Active Not Recruiting1
DB04572Thiotepa2Active Not Recruiting1